Part 2: When a Nobel-Winning Discovery Ended Up in Court — The University–Pharma Royalty Trap [Paid]

Who really invented a breakthrough cancer drug—and how much is that invention 'fairly' worth? One of the most consequential royalty disputes in the history of academic–industry collaboration pulled a Nobel Prize winner and a major pharmaceutical company into years of litigation.

It all traced back to a single licensing agreement signed more than a decade earlier. Terms that looked perfectly reasonable at the time became a powder keg once the drug turned into a multi-billion-dollar global blockbuster nobody had forecast. And around the very same patents, a parallel lawsuit was unfolding across the Pacific in the United States—this one asking a different question entirely: who counts as an inventor?

This article follows the specific royalty rates written into the contract, the rising damage claims, the settlement breakdown, and the link to the U.S. case—chronologically—to ask what, exactly, made the difference in this dispute.